In short
This article explores the use of skin autografts in clinical trials for patients undergoing reconstructive surgery after basal cell carcinoma removal. Skin autografts are a type of living tissue equivalent that uses a patient's own skin cells to create a personalized treatment. The trials aim to evaluate the safety, feasibility, and effectiveness of this innovative approach compared to traditional methods.
At a glance
- Study Type
- Phase II clinical trial
- Treatment
- Nanostructured autologous artificial skin based on fibrin matrix with agarose or hyaluronic acid
- Condition
- Basal cell carcinoma requiring reconstructive surgery
- Primary Objectives
- Safety and feasibility of skin autograft
- Secondary Objectives
- Efficacy, histological comparison, skin homeostasis, ultrasound analysis, pain assessment, aesthetic quality, quality of life impact, economic evaluation
- Key Inclusion Criteria
- Adults with basal cell carcinoma on scalp, torso, or extremities; requiring Mohs surgery
- Key Exclusion Criteria
- Locally advanced basal cell carcinoma, facial lesions (except frontal-lateral and temple areas), urgent surgical needs, infected or poorly vascularized injuries
- Primary Endpoints
- Adverse events, surgical suturability, graft adherence, and wound re-epithelialization
- Secondary Endpoints
- Epithelialization percentage, pain levels, aesthetic appearance, quality of life, structural and functional skin properties, economic efficiency
What is SKIN AUTOGRAFT?
SKIN AUTOGRAFT is an innovative medical treatment being studied for use in reconstructive surgery for patients with basal cell carcinoma. It is classified as a living tissue equivalent, which means it's designed to mimic the properties of natural human skin. This treatment is currently being investigated in a Phase II clinical trial to evaluate its safety and effectiveness compared to traditional skin grafting techniques.
Medical Conditions Treated
The primary medical condition being targeted by SKIN AUTOGRAFT is reconstructive skin surgery in basal cell cancer, specifically following Mohs surgery. Mohs surgery is a precise surgical technique used to treat skin cancer by progressively removing thin layers of cancer-containing skin and examining them until only cancer-free tissue remains.
How It Works
SKIN AUTOGRAFT is a type of nanostructured autologous artificial skin based on a fibrin matrix combined with either agarose or hyaluronic acid. Here's a breakdown of what this means:
- Autologous: The treatment uses the patient's own cells, reducing the risk of rejection.
- Nanostructured: The skin substitute is engineered at a very small scale, allowing for precise control of its properties.
- Fibrin matrix: Fibrin is a protein involved in blood clotting and wound healing, providing a scaffold for cell growth.
- Agarose or hyaluronic acid: These substances help create a structure that mimics natural skin tissue.
The artificial skin is designed to be surgically implanted into the area where skin cancer has been removed, potentially offering a more advanced alternative to traditional skin grafts.
Clinical Trial Objectives
The main objectives of the clinical trial for SKIN AUTOGRAFT are:
- Safety: To confirm that the use of this artificial skin is safe, based on the incidence of adverse events during implantation and follow-up.
- Feasibility: To verify that the surgical implant is practical in terms of its ability to be sutured, attach to the recipient tissue, maintain integrity, and facilitate wound healing.
- Efficacy: To analyze whether SKIN AUTOGRAFT is as effective or more effective than traditional autografts in terms of wound healing and overall outcomes.
Secondary objectives include comparing the histological properties of the implanted artificial skin to natural skin, studying skin homeostasis, analyzing ultrasound differences, comparing pain levels, assessing scar quality and impact on quality of life, and conducting an economic evaluation of the treatment.
Eligibility Criteria
To participate in the clinical trial for SKIN AUTOGRAFT, patients must meet certain criteria. Some key inclusion criteria are:
- Adults aged 18 or older
- Diagnosed with basal cell carcinoma on the scalp, torso, or extremities
- Lesions that require Mohs surgery and cannot be closed with direct suture or flaps
Some exclusion criteria include:
- Locally advanced basal cell carcinoma with deep tissue infiltration
- Lesions on the face (except for frontal-lateral area and temple)
- Pregnant or breastfeeding women
- Known allergies to certain antibiotics used in the manufacturing process
It's important to note that these are just some of the criteria, and a healthcare professional would need to assess each individual case.
Safety and Efficacy
The clinical trial is designed to carefully evaluate the safety and efficacy of SKIN AUTOGRAFT. Safety measures include monitoring for adverse events, complications, and sequelae in the healing process. Efficacy will be assessed through various means, including:
- Percentage of epithelialization (skin healing) 3 weeks after surgery
- Time until stitches can be removed
- Time until complete healing
- Pain levels experienced by patients
- Aesthetic appearance of the treated area
- Impact on quality of life
Additionally, advanced techniques such as doppler ultrasound, cutaneous homeostasis studies, and histological tests will be used to evaluate the structural and functional properties of the treated skin.
Potential Benefits
While the full benefits of SKIN AUTOGRAFT are still being studied, potential advantages over traditional skin grafts may include:
- Improved healing and integration with surrounding tissue
- Reduced pain and complications at the donor site (as no separate donor site may be needed)
- Better aesthetic outcomes
- Improved quality of life for patients
It's important to remember that these potential benefits are still being investigated in the clinical trial, and more research is needed to confirm the advantages of this innovative treatment.